Terms: = Prostate cancer AND SUZ12, CHET9, 23512, ENSG00000178691, Q15022, KIAA0160, JJAZ1 AND Treatment
6 results:
1. Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective treatment of Castration-Resistant prostate cancer.
Han Z; Rimal U; Khatiwada P; Brandman J; Zhou J; Hussain M; Viola RE; Shemshedini L
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36288553
[TBL] [Abstract] [Full Text] [Related]
2. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.
Shankar E; Franco D; Iqbal O; Moreton S; Kanwal R; Gupta S
Toxicol Appl Pharmacol; 2020 Oct; 404():115200. PubMed ID: 32805266
[TBL] [Abstract] [Full Text] [Related]
3. ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.
Mochmann LH; Neumann M; von der Heide EK; Nowak V; Kühl AA; Ortiz-Tanchez J; Bock J; Hofmann WK; Baldus CD
Oncotarget; 2014 Jan; 5(2):351-62. PubMed ID: 24504051
[TBL] [Abstract] [Full Text] [Related]
4. Aberrations of EZH2 in cancer.
Chase A; Cross NC
Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
[TBL] [Abstract] [Full Text] [Related]
5. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
Glinsky GV
J Clin Oncol; 2008 Jun; 26(17):2846-53. PubMed ID: 18539963
[TBL] [Abstract] [Full Text] [Related]
6. Integration of HapMap-based SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes.
Glinsky GV
Cell Cycle; 2006 Nov; 5(22):2613-25. PubMed ID: 17172834
[TBL] [Abstract] [Full Text] [Related]
